Trevor Sweatman

Trevor Sweatman, Ph.D., Director of Clinical Pharmacology for Paradox, is a Professor of Pharmacology at The University of Tennessee Health Science Center with over 30 years of experience in qualitative and quantitative drug analysis of clinical samples, pharmacokinetics, and cancer drug development. Dr. Sweatman has an extensive track record of publication and NIH funding in the development, mechanistic analyses, and preclinical and clinical testing of novel anthracycline compounds, including Valstar®, an FDA-approved agent for the treatment of bladder cancer.

He is a member of the UT Center for Cancer Research and has formerly been an Associate Editor of Clinical Cancer Research, Representative to The United States Pharmacopeia Convention, and Consultant in Pharmacology, Huntington Medical Research Institute (Pasadena, CA).

Dr. Sweatman earned a B.Sc (honors) in Applied Biology from Hatfield Polytechnic (UK) and Ph.D. with the Clinical Pharmacology group from Southampton University Medical School (UK), followed by post-doctoral training in Pharmacology at the Dana-Farber Cancer Institute.